Maintains microbiological sterility of peptide solutions through benzyl alcohol antimicrobial activity across multiple withdrawals
Daily dose: 2,330mcg (2.33mg) total blend This breaks down to approximately: 1,700mcg (1.7mg) GHK-Cu 330mcg TB-500 330mcg BPC-157 Administration: Once daily, subcutaneous injection Cycle length: 4 weeks, followed by 2-4 week rest period Schedule: Daily injection at consistent time For a standard 70mg glow peptide vial reconstituted with 3mL bacteriostatic water, this protocol requires 0.10mL (10 units on an insulin syringe) per daily injection
AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin-resistant mice
Symptom Relief: May reduce abdominal pain, bloating, diarrhea, and discomfort associated with intestinal damage or inflammation
Most of the existing research on BPC-157 has been conducted in laboratory and animal settings
More sales or programs are needed to keep patients on track and engaged